International Journal of Endocrinology

International Journal of Endocrinology / 2016 / Article

Research Article | Open Access

Volume 2016 |Article ID 8129497 | 9 pages | https://doi.org/10.1155/2016/8129497

Predictive Factors of Development of Graves’ Ophthalmopathy for Patients with Juvenile Graves’ Disease

Academic Editor: Giuseppe Damante
Received07 Mar 2016
Accepted12 May 2016
Published16 Jun 2016

Abstract

Background. Due to low incidence of Graves’ ophthalmopathy (GO) among children, the manifestation is poorly analyzed, posing a risk to late identification of insidious disease. Purposes. To identify predictive factors that may influence the development of GO in pediatric and young patients with Graves’ disease (GD). Methods. A cross-sectional study of patients newly diagnosed with pediatric or juvenile GD during 2002–2012 was conducted at the Hospital of Lithuanian University of Health Sciences. Ocular evaluation was based on European Group on Graves’ Orbitopathy survey. The ocular manifestations were analyzed in relation to demographic, environmental, and clinical factors. Results. In total, 130 patients with juvenile GD were included; 29.2% had GO. Median age at GD onset was 17 yrs (IQR 4–29). Main symptoms of GO were eyelids retraction (73.7%), proptosis (65.8%), injection of conjunctiva (42.1%), and eyeball motility disturbance (21.1%). Major significant and independent risk factors for GO development were high initial concentration of FT4 (OR = 5.963), TTHAb (OR = 6.358), stress (OR = 6.030), and smoking (OR = 7.098). Conclusion. The major factors that could influence GO development were smoking, stress, and increased levels of initial TRAb, FT4. Slight proptosis, retraction of eyelids, and conjunctive injection were found as predominant ophthalmological symptoms in juvenile GO.

1. Introduction

Graves’ disease (GD) is autoimmune disorder caused by autoantibodies that activate the thyrotropin receptor (TSH-R) and this results in stimulating thyroid gland to synthesize and secrete thyroid hormones [1]. GD affects the thyroid gland (diffusely enlarged goiter), the orbital and periorbital tissues (ophthalmopathy), and in rare cases pretibial skin or digits (dermatopathy or thyroid acropachy) [24].

GD is the most common cause of hyperthyroidism in children and adolescents [59]. Graves’ disease accounts for 10–15% of all childhood thyroid diseases and is rare in subjects below 5 years of age [10, 11]. Some studies indicate that the incidence of juvenile GD is increasing [8, 12]. Juvenile GD as multifactorial disease is associated with a family history of autoimmune thyroid disease or other autoimmune disorders, environmental and hormonal factors, and the immune system disorders [13]. There is no single factor leading to clinical outcome of the disease [14]. However, the studies on risk factors show heterogeneous and diffuse findings.

As mentioned above, in some Graves’ disease cases the ophthalmopathy occurs, which is called Graves’ ophthalmopathy (GO). The incidence of GO in children is very low, about 1.7 to 3.5 cases per 100,000 population per year [15, 16]. The clinical manifestation of GO in children and adolescents is usually mild [17], self-limited, and occurring during the acute hyperthyroid state [18]. Severe ophthalmopathy in pediatric age is uncommon [15, 19, 20]. Due to low incidence of GO among children, the manifestation is poorly analyzed, mainly investigated only in adults [21, 22]. This poses a risk to identify the signs of insidious disease too late.

Results from psychological studies show that GO has negative impact on the quality of life and causes psychological disorders and emotional distress due to either predominant disfiguring eye signs or the cosmetics changes [21, 23, 24]. Nexo et al. (2014) study suggests that patients with Graves’ disease have a great risk of work disability and unemployment [25].

With this study we aimed to evaluate the signs of juvenile Graves’ ophthalmopathy and identify the predictive factors that may influence the development of Graves’ ophthalmopathy in children and young adults with Graves’ disease.

2. Material and Methods

We designed and conducted a cross-sectional study in 2014 at Department of Ophthalmology, Hospital of Lithuanian University of Health Sciences. The sample of the study is comprised of subjects enrolled from database of the Hospital of Lithuanian University of Health Sciences who have been diagnosed with incident of Graves’ disease at the age below 30 years, during the period 2002–2012. Eligibility criteria for patients were as follows:(i)Inclusion criteria: Graves’ disease diagnosed at younger age than 30 years and absence of ophthalmological or systemic diseases.(ii)Exclusion criteria: patient being not available for evaluation and presence of other ophthalmological or systemic diseases.The study protocol was approved by Kaunas Regional Biomedical Research Ethics Committee (No. BE-2-40, 2011). Every study subject or his/her parents or guardians (if subject was minor) have signed informed consent form.

The diagnosis of GD was made by endocrinologist and based on commonly accepted clinical and laboratory criteria: clinical symptoms of hyperthyroidism, increased concentrations of free thyroxin (FT4), free triiodothyronine (FT3), suppressed thyrotropin (TSH) concentrations, increased serum concentrations of TSH receptor antibodies (TRAb), and diffuse goiter on ultrasound. The following parameters from medical records of patients diagnosed with GD were recorded: age at GD onset, gender, concentrations of FT3, FT4, TTH, TRAb, antiperoxidase antibodies, (antiTPO) and antibodies against thyroglobulin (antiTg), goiter size by palpation, treatment, and ocular findings at the onset of disease. Physical examination of the thyroid was performed by endocrinologist and thyroid size was graded according to the criteria recommended by the World Health Organization [WHO].

Ophthalmological assessment was made based on European Group on Graves’ Orbitopathy (EUGOGO) survey (2008). The following ophthalmological findings were recorded: best-corrected visual acuity using autophoropter “Nidek RT-3100” (Nidek, Japan) and optotypes projector “Nidek CP-770” (Nidek, Japan), slit-lamp investigation (TAKAGI SEIKO, SM-4N, Japan, 2008), intraocular pressure obtained by device “Auto Refractometer/Keratometer/Tonometer TONOREF II” (Nidek, Japan), proptosis measured by Hertel’s exophthalmometry (in millimeters), monocular ductions (in degrees), eyelid signs (lid aperture, upper and lower lid retraction; normal upper eyelid position was considered to be 1–1.5 mm below superior limbus; normal lower eyelid position was considered to be at the level of inferior limbus), and indirect ophthalmoscopy (“Volk super 66 D lens,” Volk Optical, Inc.). The ocular manifestation was analyzed in relation to the thyroid disease course (remissions and recurrence episodes), clinical manifestation of disease, putative risk factors, family history of thyroid disorders, smoking habits, and duration of treatment of thyroid disease.

2.1. Statistical Analysis

Statistical analysis was performed using “SPSS for Windows” version 20.0 (SPSS Inc., Illinois, USA). The continuous variables were described as mean values ± standard deviation (SD) or median (with interquartile range IQR), while the categorical variables were described as numbers and percentages. The Kolmogorov-Smirnov test was used to test the normality of distribution of continuous variables and based on that the parametric or nonparametric tests were subsequently chosen. In bivariate analyses, the independent samples -test or Mann-Whitney test was used for the comparison of continuous variables between two independent groups. For comparisons of categorical variables, chi-square or Fisher exact test was used. For two continuous indicators, the Spearman correlation was calculated. For evaluation of the effect of risk factors on Graves’ ophthalmopathy development in Graves’ disease patients, the univariate and multivariate linear regression analysis were conducted with odds ratios as effect estimates. The median values of biochemical results were chosen as cut-off point used in the analysis.

The level of statistical significance was set at for all the tests.

3. Results

3.1. Study Sample

In total, 130 patients with juvenile GD were evaluated for signs of GO. For 38 (29.2%) ophthalmological signs of GO were present. General and disease characteristics of study sample () are presented in Table 1.


VariableGO(–) ()GO(+) () value
Mean SDMedian (IQR)Mean SDMedian (IQR)

Age, years23 (6.0)24 (17–28)22 (7.0)23 (16–28)0.468
Gender
 Female, % ()91.3 (84)76.3 (29)0.021
 Male, % ()8.7 (8)23.7 (9)
Ethnicity
 Caucasian, % ()100 (130)
BMI, kg/m220.68 (19.15–22.33)20.76 (19.17–22.09)0.938
Duration of GD, months72 (8–122)
Treatment, % ()
 ATD MMI/PTU54.6 (71)/4.6 (6)22.3 (29)/2.3 (3)0.916/0.720
 Thyroidectomy11.5 (15)4.6 (6)0.942
 Radioactive iodine2.3 (3)1.5 (2)0.589

GO (−): Graves’ disease patients without Graves’ ophthalmopathy; GO (+): Graves’ disease patients with Graves’ ophthalmopathy; BMI: body mass index; ATD: antithyroid drug; MMI: methimazole; PTU: propylthiouracil.

82% of GO patients had first ophthalmological signs before the diagnosis of GD. After the GD diagnosis, the median time to development of GO was 1 month (minimum 0 and maximum 24 months). The diagnosis of juvenile Graves’ ophthalmopathy was based on clinical symptoms and signs. The most common complaints were bulging eyes (76.3%), tearing (42.1%), and photophobia (31.6%). In our study, the GO was in active form in 21.1% of total GO cases; the clinical activity score (CAS) was ≥3 symptoms from maximum 7. The most frequent objective symptoms were eyelids (upper or/and lower) retraction 73.7%, slight proptosis (65.8%), and injection of conjunctiva 42.1%. Eye motility was limited in 21.1% of GO cases, but only in extreme gazes, corneal staining was found in 5.3%, while the optic neuropathy signs were not found.

3.2. Bivariate Risk Factor Analysis

We analyzed the associations of putative risk factors on the development of GO among GD patients (Table 2). Comparing probable biomedical risk factors for GD, we found significantly more frequent positive family history of thyroid disease in two generations of relatives in GO (+) group. The thyroid gland size in palpitation was found larger in GO (+) group. Other clinical risk factors did not influence the occurrence of GO. 5.6% (2) of Graves’ disease patients smoked in adolescence (up to 18 years old) and 12.8% (12) older than 18 years. 21.5% (28) of patients mentioned that they felt physically stressful event in one-year period before GD signs were presented.


FactorGO (−)GO (+) value

Thyroid disease in family38.0 (35)68.4 (26)0.002
Loss of weight56.5 (52)60.5 (23)0.670
Drug-induced hypothyroidism8.7 (8)18.4 (7)0.114
Thyroid gland volume (clinical assessment)
 I°27.2 (25)13.2 (5)<0.001
 II°56.5 (52)34.2 (13)
 III°16.3 (15)52.6 (20)
Smoking3.1 (4)7.7 (10)<0.001
Work character
 Does not work11.5 (15)3.8 (5)0.761
 Intellectual 51.5 (67)23.1 (30)
 Physical 7.7 (10)2.3 (3)
Stress10.0 (13)11.5 (15)<0.001

The median age at Graves’ disease diagnosis of all patients was 17 (4–29) years, in pediatric group critical age for appearance of Graves’ disease symptoms was 14 (12–16) years, and in young adults was 21 (19–24) years. Comparing the age of GD onset between GO (+) and GO (−) groups the statistically important difference was not found.

Analyzing the course of Graves’ disease, we found that relapses of GD during first 2 years after the remission was achieved were significantly more frequent in GO (+) compared to GO (−) group 60.5% (23) versus 38.0% (35) (). The duration of first remission was longer than one year for 57.6% (54) in GO (−) and 28.9% (11) in GO (+) ().

Biochemical results at diagnosis are presented in Table 3. FT4, FT3, TRAb, and antiTPO concentrations at diagnosis were found to be significantly higher in the GO (+) compared to GO (−) group (Table 3).


GO (−)GO (+) value

FT4, pmol/L32.40 (25.50–48.88)59.19 (39.90–77.20)<0.001
FT3, pmol/L8.86 (6.80–14.77)20.87 (11.57–28.80)<0.001
TSH, mIU/L0.01 (0.01–0.01)0.01 (0.01–0.02)0.162
TRAb, U/L10.40 (4.90–22.00)38.25 (23.58–61.43)<0.001
AntiTPO, kU/L68.00 (15.90–388.69)146.00 (56.00–506.63)0.045
AntiTg, kU/mL 92.50 (14.50–346.25)39.30 (14.00–620.00)0.641

3.3. Multivariate Risk Factor Analysis

For identification of independent risk factors for GO development in GD patients we conducted two-step logistic regression. In the first step we checked 12 putative factors that could influence the GO development. Univariate logistic regression analysis revealed higher TRAb concentration at the beginning of GD (OR = 10.00) and smoking (OR = 7.86). Detailed results from univariate regression analysis are presented in Table 4.


FactorValueβOR95% CI

GenderFemale1.000
Male1.1813.2591.1509.2350.026

SmokingNo1.000
Yes2.0617.8572.28527.0170.001

Family history of thyroid diseaseNo1.000
Yes1.2613.5291.5817.8780.002

Drug-induced hypothyroidismNo1.000
Yes0.8632.3710.7937.0860.122

Stress before GDNo1.000
Yes1.3773.9631.6519.5160.002

FT4, pmol/L0–35.991.000
36.00+1.7645.8332.40714.137<0.001

FT3, pmol/L0–11.991.000
12.00+1.5354.6431.90111.3380.001

TSH, mU/L0.020+1.000
0–0.0190.5201.6830.7653.7000.195

AntiTPO, kU/L0–791.000
80+0.5261.6920.7733.7060.188

TRAb, U/L0–15.991.000
16.00+2.30310.0003.48728.679<0.001

AntiTG, kU/L0–791.000
80+0.7780.2302.6280.686

Age at the diagnosis, years0–171.000
18+0.0871.0910.5122.3240.822

β: regression coefficient; OR: odds ratio; CI: confidence interval.

The multivariate regression analysis revealed four independent factors associated with GO development in GD patients, TRAb, FT4, stress, and smoking () (Table 5). However, gender, FT3, and family history of thyroid disease cannot be regarded as independent risk factors for GO (). Of note, the strongest trigger for Graves’ ophthalmopathy was smoking increasing the odds to develop the GO by more than 7 times. For comparison initial TRAb concentration 16 U/L and higher, stress, and FT4 concentration of 36 pmol/L and above were associated with almost 6 times higher odds to develop ophthalmopathy compared with absence of these risk factors.


FactorβOR95% CI

Gender1.5304.6200.94922.5020.058
Smoking1.9607.0981.26239.9290.026
Stress1.7976.0301.25129.5020.025
Family history of thyroid disease0.7362.1450.6277.3410.224
FT4, pmol/L1.7865.9631.36626.0250.018
FT3, pmol/L0.0201.0200.2853.6560.975
TRAb, U/L1.8506.3581.55825.9530.010

β: regression coefficient; OR: odds ratio; CI: confidence interval.

4. Discussion

Graves’ ophthalmopathy in young patients can not only affect visual function but also significantly impair the quality of life and lead to psychological and social problems due to manifestation of ocular symptoms that disfigure the appearance. Graves’ disease appears typically between 40 and 60 years of age [1], while juvenile GD is relatively rare. There are many studies targeted to establish the risk factors for GO among adults, but younger age group has been underinvestigated and the impact on putative risk factors is less clear. It can be hypothesized that younger patients have an advantage because they have had less exposure to risk factors related to lifetime duration; however, similar GO prevalence rates among GD cases regardless of age pose this assumption under question.

The main findings of our study indicate that juvenile GO appeared from mild to moderate stages. In our study, eye symptoms among GD patients appeared mostly within one month from GD diagnosis (varying from 0 to 24 months). The manifestation of ophthalmopathy can predict the more aggressive course of Graves’ disease. We found that elevated TRAb and FT4 titres at diagnosis of GD are useful predictive factors influencing the development of Graves’ ophthalmopathy. Smoking and stress could work as a trigger in juvenile GO development.

4.1. Prevalence of Juvenile GD/GO

We found that Graves’ ophthalmopathy developed in 29% of juvenile Graves’ disease cases. This is quite similar with data of Krassas et al. who report that in Europe GO occurred in 33% of patients with juvenile Graves’ hyperthyroidism [15]. It should be noted, however, that these estimates are lower than that found in other studies with ranging prevalence of 40–60% in juvenile GD patients [8, 12, 15, 17, 20, 2635].

Previous research suggests that childhood GO is less severe and self-limited comparing to adulthood GO [15, 31, 36, 37]. Reasons for this GO clinical difference are still unclear.

4.2. Juvenile GO Signs and Symptoms (Clinical Aspects)

The findings on clinical manifestation of juvenile GO found in our study are consistent with previous research. It has been found that most of juvenile patients presented with mild exophthalmos, eyelids abnormalities such as lid lag, and lagophthalmos, where lower lid retraction was found most frequently [28, 29, 32, 33]. Nonetheless, even pediatric patients with GD require vigilance; in rare cases severe signs of GO such as limited extraocular motility and visual threatening complications due to corneal or optic nerve involvement were observed [26, 28, 31, 3741]. Diana et al. (2014) and Holt et al. (2008) in their studies noted that the symptoms of GO in majority of prepubertal children are milder than in postpubertal children; the latter have such symptoms like restrictive strabismus, chemosis, or preorbital fat pad enlargement [29, 32].

Eyelid retraction and slight proptosis were the most predominant signs of GO in our study. Injection of conjunctiva and such symptoms as photophobia and tearing without corneal staining may be attributed to dry eye signs. Changes in ocular surface and tear film are very common in patients with thyroid disease [4244]. Although dry eye syndrome in thyroid disorders is usually considered as a complication of autoimmune condition related to Graves’ ophthalmopathy, there are several causes which could contribute to dry eye syndrome in those patients. Among such causes, lacrimal gland dysfunction due to autoimmune process, increased ocular surface exposure due to proptosis and eyelid retraction, and excess evaporation due to abnormally high tear film osmolarity may be mentioned [4548].

4.3. GO as Predictor of Aggressive GD Form

The fact that the majority (82%) of GO patients had ophthalmological complaints before the GD was identified shows the importance of collaboration of pediatricians, ophthalmologists, and endocrinologists, since the ocular symptoms may indicate the thyroid disorders. In our study, eye symptoms among GD patients appeared mostly within one month from GD diagnosis (varying from 0 to 24 months). It suggests that both Graves’ disease and Graves’ ophthalmopathy are likely to develop simultaneously. Acuna et al. (2007) also have found the temporal relationship between diagnosis of thyroid dysfunction and the onset of ophthalmic signs; they showed that these two disorders vary between 0 and 6 months (2 weeks on average), with majority of patients having some ocular signs at the time of diagnosis [16]. An explanation for simultaneous beginning of GD and GO may be the same autoimmune processes in orbit and thyroid gland [18].

Our study revealed a strong association between GO symptoms and more aggressive autoimmune disease course: patients with GO also had more frequent relapses and shorter first remission period. Similar findings were described by Gogakos et al. (2010) and Anagnostis et al. (2013) and this may be useful to endocrinologists for prediction of the risk for more frequent relapses [37, 49]. In contrast, Quadbeck et al. (2005) interpreted that thyroid-associated ophthalmopathy was not associated with relapse rate [50].

4.4. Risk Factors for GO

Though Graves’ ophthalmopathy was mentioned in medical literature in 1835 by Robert James Graves, the causal factors are still under clinical and scientific debates. The etiology of autoimmune diseases is multifactorial, involving the interaction of genetic, environmental, hormonal, and immunological factors playing the role in their development [51]. Nevertheless, the onset of at least 50% of autoimmune disorders has been attributed to unknown trigger factors [52].

We found that elevated TRAb and FT4 titres at diagnosis of GD are useful predictive factors influencing the development of Graves’ ophthalmopathy. The TSH receptor (TSHR) is an established autoantigen in GD and may play an important pathogenic role as a useful marker to determine the activity and severity of GO as well [5357].

It has been shown that TSHR expression is higher in GO orbital fat compared with normal orbital adipose tissue [53, 54, 58]; the TSHR is also expressed on the surface of lacrimal cells [45]. Acuna et al. (2007) found an association between positive TRAb levels and development of Graves’ ophthalmopathy in children with Graves’ disease, but they did not analyze the basal TSH, FT3, or FT4 concentration influence for GO development [16]. Also Diana et al. (2014) found markedly higher serum TSAb levels in the pediatric GD and GO sample compared to those with thyroid disease only [29].

TSHR antibodies are not linked to ophthalmopathy in all cases. It remains unclear why in some cases GO occurs many years after the development of Graves’ hyperthyroidism or in patients with Hashimoto’s thyroiditis in whom eye changes occur in the absence of TRAb production [59]. Therefore the results seem conflicting, showing that TRAb is not the main pathogenetic clue for development of GO.

Other thyroid antibodies, such as antiTPO, may also influence the extrathyroid manifestation, but the findings from previous studies are ambiguous. Diana et al. (2014) and Acuna et al. (2007) did not find significant association between antiTPO and GO or correlation between the levels of TRAb and antiperoxidase antibodies [16, 29]. In contrast, Besharati and Rastegar (2005) and Lee et al. (2014) found positive association between elevated antiTPO levels in children with GO [33, 60]. Khoo and associates found a significant correlation between negative antiperoxidase antibodies and Graves’ ophthalmopathy in adult patients [61]. Wright-Pascoe et al. reported that both antiTPO and antiTg correlated with GO manifestation in adults [62].

In addition, thyroid hormones are also under debates regarding impact on GO. Majority (75–80%) of GO patients present Graves’ disease as hyperthyroidism [63, 64], but GO may present in hypothyroid or even euthyroid status [65]. Lee et al. (2014) in retrospective study of 80 pediatric GD patients found that initial higher level of FT3 was associated with the presence of GO in childhood GD, but the initial serum levels of FT4 and TSH were not significantly different between the GD groups with and without GO [33]. Shibayama and colleagues (2005) did not find a relationship between concentration of FT3 and FT4 and Graves’ ophthalmopathy [35]. The recent study by Stein et al. 2015 in large cohort of adult patients with newly diagnosed GD found that among risk factors the elevated TSH and thyroid stimulating antibodies (TSI) may negatively impact GO [66]. It was found that the risk of GO increases in case of elevated TSH level, using cut-off of 7 μIU/mL.

In the present study we also tried to establish the trigger factors for juvenile GO development; one of them was cigarette smoking. Cigarette smoking as a potential risk factor for GO occurrence has been analyzed in majority of studies with conflicting results. Smoking is associated with an increased risk of development of signs of GO by 8 times (comparing with nonsmokers) [6769]. Severe GO forms and lower effect of immunosuppressive treatment in smoking GO patients are more often observed compared to nonsmoking GO patients [70, 71]. One study found that the manifestations of GO begin to resemble the adult pattern in adolescence; this could be explained by increasing smoking prevalence in adults [26]. The risk of development of more severe GO signs as proptosis and diplopia is also correlated with the number of cigarettes smoked daily [14, 53, 67, 72]. All this was supported by Lee et al. (2010) who noted that smoking status was a predictive risk factor for a severe course of GO and the development of optic neuropathy [73]. The fact that there are less severe cases in children may explain that active smoking is unusual in children. However, Abraham-Nordling et al. (2011) and Nyström et al. (2013) were not able to find a correlation between smoking and GO development [74, 75]. Kampmann et al. (2014) in prospective study reported that smoking habits did not impact severity of GO [55].

There is an interesting theory that smoking might have direct irritative actions on the eyes accounting for inflammatory changes and modulation of immune reactions in the orbit. Smoking causes partial hypoxia, which stimulates the orbital fibroblasts to synthesize glycosaminoglycans which exacerbates extraocular muscles oedema and swelling [76].

Whether passive smoking may have the same impact as active smoking is not established; however, in a European survey of GO among children, the highest prevalence of pediatric GO was found in countries where the prevalence of smokers among teenagers was also highest: since more than 50% of children were less than 10 years of age, it is likely that passive smoking rather than active smoking influenced GO occurrence [15, 20].

In the current study we noticed that GO appeared more often in patients who mentioned that within last year before GD onset they had a stressful event. They listed such situations as learning and work stress (learning problems, dropping out from school or university, speaking in front of class and colleagues, conflicts with friends and loved ones, and loss of a job) and life stresses (death of close relatives, divorce of parents, financial problems, and traumas). The emotional stress has been long considered as possible etiology of Graves’ disease, but the relationship between psychological factors and GO development is still not well known. In patients with Graves’ disease, the stress scores correlated significantly with serum TSH receptor antibody activity and thyroid volume [52]. This hypothesis suggests the conclusion that stress is a possible trigger for an increased TSAb level which affects GO development.

Our study had some limitations. It comprised a small study sample due to low incidence of juvenile Graves’ disease. In addition, we used a retrospective design for GD and GO incidence, which may also affect the findings of the study. The retrospective stage includes relatively long period and therefore we cannot exclude that some patients who were classified as having no GO might have GO signs at time of GD diagnosis. Further prospective studies are preferred to continue the assessment of relationship between thyroid disease course and extrathyroid manifestation. Nevertheless, as counterbalance to those limitations our study also had advantages, especially in terms of risk factor interactions, since younger patients have shorter exposure of negative factors.

5. Conclusion

Our findings clearly show that active smoking, stress, elevated initial TRAb, and FT4 levels played the major role in GO development for patients with juvenile Graves’ disease. GO manifestation is associated with more aggressive course of GD in children and young patients. Slight proptosis, retraction of eyelids, and conjunctive injection were found as predominant ophthalmological symptoms in juvenile GO.

Competing Interests

The authors declare that there are no competing interests regarding the publication of this paper.

References

  1. A. P. Weetman, “Graves' disease,” The New England Journal of Medicine, vol. 343, no. 17, pp. 1236–1248, 2000. View at: Publisher Site | Google Scholar
  2. K. Laubner, W. A. Weber, and J. Seufert, “Graves' ophthalmopathy from the internist's perspective,” Ophthalmologe, vol. 108, no. 5, pp. 410–416, 2011. View at: Publisher Site | Google Scholar
  3. L. Bartalena, P. E. Macchia, C. Marcocci, M. Salvi, and F. Vermiglio, “Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement,” Journal of Endocrinological Investigation, vol. 38, no. 4, pp. 481–487, 2015. View at: Publisher Site | Google Scholar
  4. L. Bartalena, “Graves' orbitopathy: imperfect treatments for a rare disease,” European Thyroid Journal, vol. 2, no. 4, pp. 259–269, 2013. View at: Publisher Site | Google Scholar
  5. S. Metso, P. Jaatinen, and J. Salmi, “Graves' disease,” The New England Journal of Medicine, vol. 359, no. 13, pp. 1408–1409, 2008. View at: Google Scholar
  6. S. A. Rivkees and D. R. Mattison, “Ending propylthiouracil-induced liver failure in children,” The New England Journal of Medicine, vol. 360, no. 15, pp. 1574–1575, 2009. View at: Google Scholar
  7. S. A. Rivkees, “Pediatric Graves' disease: controversies in management,” Hormone Research in Paediatrics, vol. 74, no. 5, pp. 305–311, 2010. View at: Publisher Site | Google Scholar
  8. S. Williamson and S. A. Greene, “Incidence of thyrotoxicosis in childhood: a national population based study in the UK and Ireland,” Clinical Endocrinology, vol. 72, no. 3, pp. 358–363, 2010. View at: Publisher Site | Google Scholar
  9. M. Kumorowicz-Kopiec, H. Dziatkowiak, J. Starzyk, T. Nizankowska-Błaz, and M. Rybakowa, “Incidence of Graves disease in children in some regions of south-eastern Poland,” Przeglad Lekarski, vol. 61, no. 8, pp. 872–875, 2004. View at: Google Scholar
  10. Z. Kraiem and R. S. Newfield, “Graves' disease in childhood,” Journal of Pediatric Endocrinology and Metabolism, vol. 14, no. 3, pp. 229–243, 2001. View at: Publisher Site | Google Scholar
  11. F. Kaguelidou, J. C. Carel, and J. Léger, “Graves' disease in childhood: advances in management with antithyroid drug therapy,” Hormone Research, vol. 71, no. 6, pp. 310–317, 2009. View at: Publisher Site | Google Scholar
  12. G. W. K. Wong and P. S. Cheng, “Increasing incidence of childhood Graves' disease in Hong Kong: a follow-up study,” Clinical Endocrinology, vol. 54, no. 4, pp. 547–550, 2001. View at: Publisher Site | Google Scholar
  13. G. Birrell and T. Cheetham, “Juvenile thyrotoxicosis; can we do better?” Archives of Disease in Childhood, vol. 89, no. 8, pp. 745–750, 2004. View at: Publisher Site | Google Scholar
  14. M. N. Stan and R. S. Bahn, “Risk factors for development or deterioration of Graves' ophthalmopathy.,” Thyroid, vol. 20, no. 7, pp. 777–783, 2010. View at: Publisher Site | Google Scholar
  15. G. E. Krassas, M. Segni, and W. M. Wiersinga, “Childhood Graves' ophthalmopathy: results of a European questionnaire study,” European Journal of Endocrinology, vol. 153, no. 4, pp. 515–520, 2005. View at: Publisher Site | Google Scholar
  16. O. M. Acuna, I. Athannassaki, and E. A. Paysse, “Association between thyroid-stimulating immunoglobulin levels and ocular findings in pediatric patients with Graves disease,” Transactions of the American Ophthalmological Society, vol. 105, pp. 146–151, 2007. View at: Google Scholar
  17. S. M. Goldstein, W. R. Katowitz, T. Moshang, and J. A. Katowitz, “Pediatric thyroid-associated orbitopathy: the children's hospital of philadelphia experience and literature review,” Thyroid, vol. 18, no. 9, pp. 997–999, 2008. View at: Publisher Site | Google Scholar
  18. T. D. Nebesio and E. A. Eugster, “Images in clinical medicine. Delayed Graves' ophthalmopathy,” The New England Journal of Medicine, vol. 362, no. 18, article e60, 2010. View at: Publisher Site | Google Scholar
  19. A. J. Bauer, “Approach to the pediatric patient with Graves' disease: when is definitive therapy warranted?” The Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 3, pp. 580–588, 2011. View at: Publisher Site | Google Scholar
  20. G. E. Krassas, “Childhood Graves' orbitopathy,” in Graves' Orbitopathy: A Multidisciplinary Approach, W. M. Wiersinga and G. J. Kahaly, Eds., pp. 239–247, Karger, Basel, Switzerland, 2010. View at: Google Scholar
  21. S. Estcourt, A. G. Quinn, and B. Vaidya, “Quality of life in thyroid eye disease: impact of quality of care,” European Journal of Endocrinology, vol. 164, no. 5, pp. 649–655, 2011. View at: Publisher Site | Google Scholar
  22. Y. Hiromatsu, H. Eguchi, J. Tani, M. Kasaoka, and Y. Teshima, “Graves' ophthalmopathy, Graves' disease, epidemiology, prevalence, ethnicity,” Internal Medicine, vol. 53, no. 5, pp. 353–360, 2014. View at: Publisher Site | Google Scholar
  23. M. Farid, A.-C. Roch-Levecq, L. Levi, B. L. Brody, D. B. Granet, and D. O. Kikkawa, “Psychological disturbance in Graves ophthalmopathy,” Archives of Ophthalmology, vol. 123, no. 4, pp. 491–496, 2005. View at: Publisher Site | Google Scholar
  24. S. Wickwar, H. B. McBain, D. G. Ezra, S. P. Hirani, G. E. Rose, and S. P. Newman, “Which factors are associated with quality of life in patients with Graves' orbitopathy presenting for orbital decompression surgery?” Eye, vol. 29, no. 7, pp. 951–957, 2015. View at: Publisher Site | Google Scholar
  25. M. A. Nexo, T. Watt, J. Pedersen et al., “Increased risk of long-term sickness absence, lower rate of return to work, and higher risk of unemployment and disability pensioning for thyroid patients: a danish register-based cohort study,” The Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 9, pp. 3184–3192, 2014. View at: Publisher Site | Google Scholar
  26. G. E. Krassas and A. Gogakos, “Thyroid-associated ophthalmopathy in juvenile Grave's disease-clinical, endocrine and therapeutic aspects,” Journal of Pediatric Endocrinology and Metabolism, vol. 19, no. 10, pp. 1193–1206, 2006. View at: Google Scholar
  27. G. E. Krassas and P. Perros, “Prevention of thyroid associated-ophthalmopathy in children and adults: current views and management of preventable risk factors,” Pediatric Endocrinology Reviews, vol. 4, no. 3, pp. 218–224, 2007. View at: Google Scholar
  28. W. Chan, G. W. K. Wong, D. S. P. Fan, A. C. K. Cheng, D. S. C. Lam, and J. S. K. Ng, “Ophthalmopathy in childhood Graves' disease,” British Journal of Ophthalmology, vol. 86, no. 7, pp. 740–742, 2002. View at: Publisher Site | Google Scholar
  29. T. Diana, R. S. Brown, A. Bossowski et al., “Clinical relevance of thyroid-stimulating autoantibodies in pediatric Graves' disease—a multicenter study,” The Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 5, pp. 1648–1655, 2014. View at: Publisher Site | Google Scholar
  30. V. D. Durairaj, G. B. Bartley, and J. A. Garrity, “Clinical features and treatment of graves ophthalmopathy in pediatric patients,” Ophthalmic Plastic and Reconstructive Surgery, vol. 22, no. 1, pp. 7–12, 2006. View at: Publisher Site | Google Scholar
  31. J. Eha, S. Pitz, and J. Pohlenz, “Clinical features of pediatric Graves' orbitopathy,” International Ophthalmology, vol. 30, no. 6, pp. 717–721, 2010. View at: Publisher Site | Google Scholar
  32. H. Holt, D. G. Hunter, J. Smith, and L. R. Dagi, “Pediatric Graves' ophthalmopathy: the pre- and postpubertal experience,” Journal of American Association for Pediatric Ophthalmology and Strabismus, vol. 12, no. 4, pp. 357–360, 2008. View at: Publisher Site | Google Scholar
  33. J. H. Lee, S. H. Park, D. G. Koh, and B. K. Suh, “Thyroid peroxidase antibody positivity and triiodothyronine levels are associated with pediatric Graves' ophthalmopathy,” World Journal of Pediatrics, vol. 10, no. 2, pp. 155–159, 2014. View at: Publisher Site | Google Scholar
  34. J. Sherman, G. B. Thompson, A. Lteif et al., “Surgical management of Graves disease in childhood and adolescence: an institutional experience,” Surgery, vol. 140, no. 6, pp. 1056–1062, 2006. View at: Publisher Site | Google Scholar
  35. K. Shibayama, Y. Ohyama, Y. Yokota, S. Ohtsu, N. Takubo, and N. Matsuura, “Assays for thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins in children with Graves' Disease,” Endocrine Journal, vol. 52, no. 5, pp. 505–510, 2005. View at: Publisher Site | Google Scholar
  36. “Diseases of the thyroid in childhood and adolescence,” in Pediatric & Adolescent Medicine, G. E. Krassas, S. A. Rivkees, and W. Kiess, Eds., vol. 11, pp. 192–209, Karger, Basel, Switzerland, 2007. View at: Google Scholar
  37. A. I. Gogakos, K. Boboridis, and G. E. Krassas, “Pediatric aspects in Graves' orbitopathy,” Pediatric Endocrinology Reviews, vol. 7, supplement 2, pp. 234–244, 2010. View at: Google Scholar
  38. A. Grüters, “Ocular manifestations in children and adolescents with thyrotoxicosis,” Experimental and Clinical Endocrinology & Diabetes, vol. 107, supplement 5, pp. S172–S174, 1999. View at: Publisher Site | Google Scholar
  39. S. H. Uretsky, J. S. Kennerdell, and J. P. Gutai, “Graves' ophthalmopathy in childhood and adolescence,” Archives of Ophthalmology, vol. 98, no. 11, pp. 1963–1964, 1980. View at: Publisher Site | Google Scholar
  40. W. M. Wiersinga, M. F. Prummel, and C. B. Terwee, “Effects of Graves' ophthalmopathy on quality of life,” Journal of Endocrinological Investigation, vol. 27, no. 3, pp. 259–264, 2004. View at: Publisher Site | Google Scholar
  41. L. A. Young, “Dysthyroid ophthalmopathy in children,” Journal of Pediatric Ophthalmology and Strabismus, vol. 16, no. 2, pp. 105–107, 1979. View at: Google Scholar
  42. V. Achtsidis, N. Tentolouris, S. Theodoropoulou et al., “Dry eye in Graves' ophthalmopathy: correlation with corneal hypoesthesia,” European Journal of Ophthalmology, vol. 23, no. 4, pp. 473–479, 2013. View at: Publisher Site | Google Scholar
  43. E. M. Rocha, F. Mantelli, L. F. Nominato, and S. Bonini, “Hormones and dry eye syndrome: an update on what we do and don't know,” Current Opinion in Ophthalmology, vol. 24, no. 4, pp. 348–355, 2013. View at: Publisher Site | Google Scholar
  44. J. H. Selter, A. I. Gire, and S. Sikder, “The relationship between Graves’ ophthalmopathy and dry eye syndrome,” Clinical Ophthalmology, vol. 31, no. 9, pp. 57–62, 2015. View at: Google Scholar
  45. A. K. Eckstein, A. Finkenrath, A. Heiligenhaus et al., “Dry eye syndrome in thyroid-associated ophthalmopathy: lacrimal expression of TSH receptor suggests involvement of TSHR-specific autoantibodies,” Acta Ophthalmologica Scandinavica, vol. 82, no. 3, pp. 291–297, 2004. View at: Publisher Site | Google Scholar
  46. M. A. Harris, T. Realini, J. P. Hogg, and J. A. Sivak-Callcott, “CT dimensions of the lacrimal gland in Graves orbitopathy,” Ophthalmic Plastic and Reconstructive Surgery, vol. 28, no. 1, pp. 69–72, 2012. View at: Publisher Site | Google Scholar
  47. G. Iskeleli, Y. Karakoc, and A. Abdula, “Tear film osmolarity in patients with thyroid ophthalmopathy,” Japanese Journal of Ophthalmology, vol. 52, no. 4, pp. 323–326, 2008. View at: Publisher Site | Google Scholar
  48. R. Moncayo, I. Baldissera, C. Decristoforo, D. Kendler, and E. Donnemiller, “Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111In-octreotide,” Thyroid, vol. 7, no. 1, pp. 21–29, 1997. View at: Publisher Site | Google Scholar
  49. P. Anagnostis, F. Adamidou, S. A. Polyzos et al., “Predictors of long-term remission in patients with Graves' disease: a single center experience,” Endocrine, vol. 44, no. 2, pp. 448–453, 2013. View at: Publisher Site | Google Scholar
  50. B. Quadbeck, R. Hoermann, U. Roggenbuck, S. Hahn, K. Mann, and O. E. Janssen, “Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease,” Thyroid, vol. 15, no. 9, pp. 1047–1054, 2005. View at: Publisher Site | Google Scholar
  51. M. Cappa, C. Bizzarri, and F. Crea, “Autoimmune thyroid diseases in children,” Journal of Thyroid Research, vol. 2011, Article ID 675703, 13 pages, 2011. View at: Publisher Site | Google Scholar
  52. L. Stojanovich and D. Marisavljevich, “Stress as a trigger of autoimmune disease,” Autoimmunity Reviews, vol. 7, no. 3, pp. 209–213, 2008. View at: Publisher Site | Google Scholar
  53. R. S. Bahn, “Current insights into the pathogenesis of Graves' ophthalmopathy,” Hormone and Metabolic Research, vol. 47, no. 10, pp. 773–778, 2015. View at: Publisher Site | Google Scholar
  54. L. R. Dragan, S. R. Seiff, and D. C. Lee, “Longitudinal correlation of thyroid-stimulating immunoglobulin with clinical activity of disease in thyroid-associated orbitopathy,” Ophthalmic Plastic and Reconstructive Surgery, vol. 22, no. 1, pp. 13–19, 2006. View at: Publisher Site | Google Scholar
  55. E. Kampmann, T. Diana, M. Kanitz, D. Hoppe, and G. J. Kahaly, “Thyroid stimulating but not blocking autoantibodies are highly prevalent in severe and active thyroid-associated orbitopathy: a prospective study,” International Journal of Endocrinology, vol. 2015, Article ID 678194, 5 pages, 2015. View at: Publisher Site | Google Scholar
  56. S. D. Lytton, K. A. Ponto, M. Kanitz, N. Matheis, L. D. Kohn, and G. J. Kahaly, “A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy,” The Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 5, pp. 2123–2131, 2010. View at: Publisher Site | Google Scholar
  57. K. A. Ponto, M. Kanitz, P. D. Olivo, S. Pitz, N. Pfeiffer, and G. J. Kahaly, “Clinical relevance of thyroid-stimulating immunoglobulins in Graves' ophthalmopathy,” Ophthalmology, vol. 118, no. 11, pp. 2279–2285, 2011. View at: Publisher Site | Google Scholar
  58. G. J. Kahaly, O. Shimony, Y. N. Gellman et al., “Regulatory T-cells in Graves' orbitopathy: baseline findings and immunomodulation by anti-T lymphocyte globulin,” The Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 2, pp. 422–429, 2011. View at: Publisher Site | Google Scholar
  59. J. R. Wall and H. Lahooti, “Pathogenesis of thyroid eye disease—does autoimmunity against the TSH receptor explain all cases?” Endokrynologia Polska, vol. 61, no. 2, pp. 222–227, 2010. View at: Google Scholar
  60. M. R. Besharati and A. Rastegar, “Clinical study of ophthalmopathy in patients with Graves' disease,” Asian Journal of Ophthalmology, vol. 7, no. 3, pp. 108–112, 2005. View at: Google Scholar
  61. D. H. C. Khoo, S. C. Ho, L. L. Seah et al., “The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy,” Thyroid, vol. 9, no. 12, pp. 1175–1180, 1999. View at: Publisher Site | Google Scholar
  62. R. Wright-Pascoe, M. F. Smikle, E. N. Barton, and O. B. James, “Limited usefulness of antithyroperoxidase and antithyroglobulin assays in Jamaicans with Graves' disease,” Human Antibodies, vol. 9, no. 3, pp. 161–164, 1999. View at: Google Scholar
  63. J. H. Lazarus, “Epidemiology of Graves' orbitopathy (GO) and relationship with thyroid disease,” Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 26, no. 3, pp. 273–279, 2012. View at: Publisher Site | Google Scholar
  64. J. H. Lazarus and M. Marino, “Orbit-thyroid relationship,” in Graves' Orbitopathy: A Multidisciplinary Approach, W. M. Wiersinga and G. J. Kahaly, Eds., pp. 26–32, Karger, Basel, Switzerland, 2010. View at: Google Scholar
  65. I. Cozma, L. S. Cozma, R. L. Boyce, M. E. Ludgate, J. H. Lazarus, and C. M. Lane, “Variation in thyroid status in patients with graves' orbitopathy,” Acta Endocrinologica, vol. 5, no. 2, pp. 191–198, 2009. View at: Publisher Site | Google Scholar
  66. J. D. Stein, D. Childers, S. Gupta et al., “Risk factors for developing thyroid-associated ophthalmopathy among individuals with graves disease,” JAMA Ophthalmology, vol. 133, no. 3, pp. 290–296, 2015. View at: Publisher Site | Google Scholar
  67. L. Bartalena, C. Marcocci, F. Bogazzi et al., “Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy,” The New England Journal of Medicine, vol. 338, no. 2, pp. 73–78, 1998. View at: Publisher Site | Google Scholar
  68. I. A. Holm, J. E. Manson, K. B. Michels, E. K. Alexander, W. C. Willett, and R. D. Utiger, “Smoking and other lifestyle factors and the risk of graves' hyperthyroidism,” Archives of Internal Medicine, vol. 165, no. 14, pp. 1606–1611, 2005. View at: Publisher Site | Google Scholar
  69. S. Putta-Manohar and P. Perros, “Epidemiology of Graves' orbitopathy,” Pediatric Endocrinology Reviews, vol. 7, supplement 2, pp. 182–185, 2010. View at: Google Scholar
  70. L. Bartalena, L. Baldeschi, A. Dickinson et al., “Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO,” European Journal of Endocrinology, vol. 158, no. 3, pp. 273–285, 2008. View at: Publisher Site | Google Scholar
  71. L. Bartalena, “The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy,” The Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 3, pp. 592–599, 2011. View at: Publisher Site | Google Scholar
  72. W. M. Wiersinga, “Smoking and thyroid,” Clinical Endocrinology, vol. 79, no. 2, pp. 145–151, 2013. View at: Publisher Site | Google Scholar
  73. J. H. Lee, S. Y. Lee, and J. S. Yoon, “Risk factors associated with the severity of thyroid-associated orbitopathy in Korean patients,” Korean Journal of Ophthalmology, vol. 24, no. 5, pp. 267–273, 2010. View at: Publisher Site | Google Scholar
  74. M. Abraham-Nordling, K. Byström, O. Törring et al., “Incidence of hyperthyroidism in Sweden,” European Journal of Endocrinology, vol. 165, no. 6, pp. 899–905, 2011. View at: Publisher Site | Google Scholar
  75. H. F. Nyström, S. Jansson, and G. Berg, “Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003–2005,” Clinical Endocrinology, vol. 78, no. 5, pp. 768–776, 2013. View at: Publisher Site | Google Scholar
  76. T. J. Cawood, P. Moriarty, C. O'Farrelly, and D. O'Shea, “Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link,” The Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 1, pp. 59–64, 2007. View at: Publisher Site | Google Scholar

Copyright © 2016 Dalia Jarusaitiene et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

1475 Views | 526 Downloads | 3 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.